CAL
DNA icon

Capital Analysts LLC’s Ginkgo Bioworks DNA Stock Holding History

Capital Analysts LLC’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9K Hold
918
– – ﹤0.01% 1301
2026
Q1 		$6K Sell
918
-216
-19% -$1.8K ﹤0.01% 1332
2025
Q4 		$9K Hold
1,134
– – ﹤0.01% 1257
2025
Q3 		$17K Hold
1,134
– – ﹤0.01% 1102
2025
Q2 		$13K Hold
1,134
– – ﹤0.01% 1093
2025
Q1 		$6K Buy
+1,134
New +$11.6K ﹤0.01% 1192

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Capital Analysts LLC's DNA Position: Q2 2026 in Review

Capital Analysts LLC held its Ginkgo Bioworks (DNA) position steady in Q2 2026 at 918 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #1301.

Capital Analysts LLC first reported a position in DNA in Q1 2025 and has held it in 6 quarters since. The position peaked at $17K in Q3 2025. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Capital Analysts LLC held 918 shares of Ginkgo Bioworks worth $9K as of Q2 2026.
  • Capital Analysts LLC left its Ginkgo Bioworks share count unchanged in Q2 2026.
  • Ginkgo Bioworks made up ﹤0.01% of Capital Analysts LLC's portfolio in Q2 2026, its #1301 holding.
  • Capital Analysts LLC first reported a position in Ginkgo Bioworks in Q1 2025 and has held it in 6 quarters since.
  • Capital Analysts LLC's Ginkgo Bioworks position peaked at $17K in Q3 2025.
  • 184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Capital Analysts LLC's 13F filing for Q2 2026, filed 5 Aug 2026.